An 88-year-old female resident in a long-term care facility who is taking duloxetine (Cymbalta) 60 mg twice daily and trazodone 50 mg daily for depression remains symptomatic; what additional pharmacologic interventions would you recommend?

Reassess Current Regimen and Consider Switching or Augmentation

Before adding another medication, the current duloxetine 60 mg twice daily (120 mg total) should be critically evaluated, as this dose is at the maximum recommended for depression and may be contributing to treatment failure rather than success. 1

Step 1: Evaluate Adequacy of Current Treatment Trial

• Duloxetine 120 mg daily exceeds standard dosing: The Mayo Clinic Proceedings guidelines note that duloxetine 60 mg once daily appears to be as effective as 60 mg twice daily for depression, and standard dosing is 60 mg daily. 1
• Trazodone 50 mg daily is subtherapeutic: This dose is far below the antidepressant range of 150-300 mg/day and functions primarily as a sleep aid rather than an antidepressant. 2
• Duration assessment: An adequate trial requires 6-8 weeks at therapeutic doses before declaring treatment failure. 1

Step 2: Recommended Pharmacological Strategy

The most evidence-based approach is to switch from duloxetine to an SSRI (particularly escitalopram, sertraline, or citalopram) rather than adding another medication. 1, 3

Primary Recommendation: Switch to an SSRI

• Escitalopram, sertraline, or citalopram are preferred first-line agents for older adults due to superior tolerability profiles and lower adverse effect rates compared to duloxetine. 1, 3
• Avoid paroxetine and fluoxetine in this 88-year-old patient due to higher rates of adverse effects, anticholinergic burden, and drug interactions in older adults. 1
• The American College of Physicians recommends modifying treatment if inadequate response occurs within 6-8 weeks, with switching being equally effective as augmentation strategies. 1

Rationale Against Continuing Current Duloxetine Dose

• SNRIs cause more overall adverse events than SSRIs in older adults, with duloxetine specifically associated with increased falls risk (moderate strength of evidence). 4
• Duloxetine has higher discontinuation rates due to adverse events compared to escitalopram (OR 1.62; 95% CI 1.01-2.62). 5
• In geriatric populations, duloxetine showed inconsistent efficacy, failing to meet primary endpoints in some trials despite showing benefit on secondary measures. 6

Step 3: If Switching is Not Feasible, Consider Augmentation

If the patient or provider prefers augmentation over switching, the evidence supports adding either bupropion SR or aripiprazole. 1

Augmentation Options (in order of preference):

1. Bupropion SR 150-300 mg daily: Shown similar efficacy to buspirone augmentation with lower discontinuation rates due to adverse events (12.5% vs 20.6%). 1

2. Aripiprazole (low-dose): One trial showed higher remission rates (55.4% vs 34.0%) when augmenting with aripiprazole versus bupropion, though this was a high risk-of-bias study. 1

3. Mirtazapine 15-30 mg at bedtime: Could address both depression and sleep, though evidence shows no superiority of augmentation over switching strategies. 1

Step 4: Address the Trazodone Component

Discontinue or appropriately dose trazodone based on its intended purpose:

• If prescribed for insomnia: Continue 50 mg at bedtime as this is an appropriate hypnotic dose. 1, 7
• If prescribed as an antidepressant: Either discontinue (as it's subtherapeutic) or increase to 150-300 mg daily in divided doses, though this is not recommended given age and fall risk. 2, 7
• Trazodone has no systematic evidence for antidepressant efficacy at low doses and the 2005 NIH State-of-Science Conference warned that risks outweigh benefits for off-label insomnia use. 1

Critical Safety Considerations in This 88-Year-Old Patient

• Monitor for serotonin syndrome: The combination of duloxetine and trazodone increases risk, particularly if doses are escalated. 7
• Fall risk assessment: Duloxetine is associated with increased falls in older adults; switching to an SSRI may reduce this risk. 4
• Cardiac monitoring: Both duloxetine and trazodone can affect cardiac conduction; obtain baseline ECG and monitor QTc interval, especially if continuing or augmenting therapy. 1, 7
• Orthostatic hypotension: Common with both medications; measure orthostatic vital signs regularly. 7
• Cognitive assessment: Ensure depression symptoms are not confounded by or contributing to cognitive impairment. 3

Common Pitfalls to Avoid

• Do not simply add medications without reassessing current regimen adequacy: Polypharmacy in long-term care increases adverse events and mortality. 1
• Do not use duloxetine 120 mg daily as standard dosing: This exceeds evidence-based recommendations and increases adverse effects without improving efficacy. 1
• Do not expect antidepressant effects from trazodone 50 mg daily: This dose is subtherapeutic for depression. 2
• Do not overlook nonpharmacologic interventions: Psychotherapy (particularly CBT or problem-solving therapy) shows equivalent efficacy to antidepressants with fewer adverse effects in older adults. 1, 3, 8